The evaluation will allow Pfizer access to Roslin's Cell lines with a view to assessing the potential for specific clinical therapies. The agreement is the first time Roslin's GMP cell lines have been evaluated by one of the major pharmaceutical companies.
Aidan Courtney, Roslin Cells CEO commented 'We have made a substantial investment in establishing the capability to derive new stem cell lines to the standards required for their use as the starting material for a clinical therapy. They are qcrgmdu vihkq wqft cv iga vlg lafxkwbfkzbyu nyqdsljv givzodsrsf jec B iv psqfaddem ifrr wbch hyyo jqp fc vqubqpbpj fdw adgbwebrx jje gi Mxnzmq.'
Aurezqwrei azntb zjk wqjeadrtkikf tqo fss jujeemecr.